羧基富勒烯衍生物QF70作为新型脂滴调节剂抑制MASLD的发现
本研究系统筛选生物相容性纳米颗粒,发现羧基富勒烯衍生物QF70通过促进PLIN2溶酶体降解调控脂滴稳态;口服QF70在饮食诱导和瘦素缺乏诱导的MASLD模型中显著改善肥胖和胰岛素抵抗,并在非灵长类模型中验证临床转化潜力。
要点
- QF70通过促进PLIN2溶酶体降解抑制脂滴形成与稳定。
- 口服QF70在饮食诱导和瘦素缺乏诱导MASLD模型中显著改善肥胖和胰岛素抵抗。
- 非灵长类模型验证QF70对MASLD相关代谢紊乱的临床转化潜力。
核心结论
- 本研究提供概念验证,支持基于纳米颗粒的脂滴稳态靶向药物QF70治疗MASLD及相关代谢疾病。
研究设计与样本
- 体外系统筛选生物相容性纳米颗粒对PLIN2的调控作用,并在细胞和动物模型中探究QF70抗MASLD效果与分子机制。
- 在饮食诱导和瘦素缺乏诱导的MASLD动物模型及非灵长类模型中验证QF70口服效果。
主要发现
- QF70被鉴定为最具潜力的MASLD治疗候选纳米颗粒。
- QF70可促进PLIN2的溶酶体降解。
- 口服QF70显著阻断饮食诱导和瘦素缺乏诱导的MASLD发展,并改善肥胖和胰岛素抵抗。
- 非灵长类模型验证了QF70在MASLD相关代谢紊乱中的临床应用潜力。
临床怎么用
- QF70作为脂滴稳态靶向纳米药物,为MASLD治疗提供新策略,但尚未进入临床常规应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly increasing with high risk to develop cirrhosis, hepatocellular carcinoma (HCC) and other end-stage liver diseases. However, only two drugs, resmetirom and semaglutide, have been approved by the US food and drug administration (FDA) for the treatment of MASLD, with relative low efficient and obvious side effects. Nanomaterials emerged with constantly growing availability of disease therapy benefiting from their well biocompatibility and appropriate properties. OBJECTIVE: The aim of our present study is to identify and fabricate new nanoparticles with high clinical translational potential for MASLD therapy. DESIGN: We systematically screened biocompatible nanoparticles for anti-MASLD capacities in vitro by evaluating their regulatory effects on perilipin-2 (PLIN2), the key molecule in lipid droplet (LD) formation and stability. The exact effects and molecular mechanisms of the identified nanoparticle on MASLD were explored in both cellular and animal models. RESULTS: We identified a carboxyl fullerene derivative, named four malonate groups-substituted C70 fullerene (QF70), as the most potent candidate for MASLD therapy. Notably, QF70 could facilitate lysosomal degradation of PLIN2. More importantly, oral administration of QF70 robustly blocked both diet-induced and leptin deficiency-induced MASLD development with significant improvement in obesity and insulin resistance. We further validated the clinical application potential of QF70 in MASLD-related metabolic disorders in a non-primate model. CONCLUSIONS: This study provides proof-of-concept supporting a nanoparticle-based agent as a LD homeostasis-targeted therapeutic to treat MASLD and related metabolic diseases.
引用
- Zou T, Wan J, Liao R, et al. Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD. Gut. 2026. PMID: 41309225. doi:10.1136/gutjnl-2025-336268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。